Src and p190GAP Inhibition for TNF-Alpha Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies fail to effectively address TNFα cytotoxicity, which contributes to tissue and organ damage in diseases such as sepsis, due to a lack of understanding of the underlying mechanisms and ineffective modulation of the associated signaling pathways.
Innovation Solution
The technology modulates TNFα cytotoxicity by inhibiting the activity of Src and p190GAP, which prevents the translocation of BAD from the cytoskeleton to the mitochondria, thereby reducing apoptosis and tissue damage, using specific inhibitors like dasatinib and saracatinib, and by promoting actin polymerization to stabilize BAD in the cytoskeleton.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TNFα is administered to treat inflammatory diseases, then beneficial anti-inflammatory effects are achieved, but TNFα-induced cytotoxicity and tissue damage occur
Solution Approach 1:
The patent segments the TNFα signaling pathway into two distinct branches: the beneficial anti-inflammatory pathway (mediated by NF-κB activation) and the harmful cytotoxic pathway (mediated by JNK1 activation and BAD translocation). By specifically targeting and inhibiting only the cytotoxic branch through Src/p190GAP inhibition, the therapy preserves the beneficial anti-inflammatory effects while eliminating the harmful cytotoxicity, thus resolving the contradiction between therapeutic efficacy and tissue damage.
Solution Approach 2:
The patent introduces Src and p190GAP as intermediary targets in the TNFα signaling pathway. These intermediaries act as selective gatekeepers that control the translocation of BAD to mitochondria. By inhibiting Src/p190GAP, the patent blocks the harmful cytotoxic signal transmission without interfering with the beneficial NF-κB-mediated anti-inflammatory pathway, thereby resolving the contradiction between maintaining therapeutic efficacy and preventing tissue damage.
2Object-affected harmful factors
If BAD activity is inhibited to prevent apoptosis, then tissue damage from TNFα cytotoxicity is reduced, but beneficial apoptotic responses may be impaired
Solution Approach 1:
The patent applies local quality by specifically inhibiting BAD translocation to mitochondria in the context of TNFα-induced cytotoxicity, rather than globally inhibiting all apoptotic pathways. The Src/p190GAP inhibition selectively blocks the harmful cytotoxic pathway while preserving other beneficial apoptotic responses. This localized intervention allows the system to maintain adaptability in apoptotic response regulation while preventing tissue damage in specific pathological contexts.
3Object-affected harmful factors
If Src and p190GAP are inhibited to block BAD translocation, then TNFα-induced apoptosis is reduced, but the mechanism of action is complex and difficult to target
Solution Approach 1:
The patent extracts and isolates the specific Src/p190GAP-mediated BAD translocation mechanism from the complex TNFα signaling network. By focusing on this discrete pathway and developing targeted inhibitors against Src and p190GAP, the patent simplifies the therapeutic approach while effectively blocking the harmful apoptotic response. This extraction of the key pathological mechanism from the broader signaling complexity enables precise intervention without needing to address the entire signaling network.
Data Source
AI summary
Provided herein is technology relating to treating and/or ameliorating TNFα cytotoxicity and particularly, but not exclusively, to compositions, methods, and kits for specifically modulating BCL-2-associated death promoter (BAD) activity, for example, by modulating the activity of Src and/or p190GAP.